Onyx Newsroom, the specialist biotech and healthcare media platform, sat down with Ali Pashazadeh, CEO of Treehill Partners, for the second episode of a JPM 2026 interview series exploring the industry’s most pressing strategic questions. The conversation addressed one of the highest-stakes decisions a biotech company makes: how to select the right clinical trial partner.
The episode explores the trade-offs between specialised and large CROs in a funding environment where biotechs have, as Onyx framed it, one shot at getting study design and execution right. Ali also addressed how smaller biotech companies have successfully navigated the increasingly significant requirement for US manufacturing capability — a shift that adds both cost and complexity to development programmes, but that has become a meaningful differentiator in attracting US-based strategic partners and investors.
The discussion reflects Treehill’s front-line work with companies preparing for transactions: understanding that clinical trial execution is not just a scientific question, but a commercial and strategic one.
Watch the full interview: https://www.onyxnewsroom.com/how-do-biotechs-select-the-right-clinical-trial-partners-treehill-partners-ep-2-onyx-live-jpm-2026/
📌 Treehill Partners – helping biopharma companies optimize development strategies for both regulatory approval and commercial success, unlocking transaction optionality with strategic and financial players.